Clinical Trial Update: Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS [Phase 1, Phase 2]

View source ↗

Summary

The study reports pharmacokinetic evaluation of rasburicase in patients with leukemia or lymphoma who are at high risk of tumor lysis syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Tumor Lysis Syndrome

Drugs mentioned

• Rasburicase (rasburicase)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Lymphoma | Phase 1, Phase 2 | Status: COMPLETED